tbuckley/cabot-search huggingface dataset:
Solitary pulmonary nodules (SPNs): Outcome of 6-year follow-up by a VA multidisciplinary lung cancer group.
Authors: H. B. Niell, J. P. Griffin, H. Cole, J. Salazar, D. Weiman, J. A. Kaufman, M. Zaman, E. V. Thompson, N. Appling
Journal: Journal of Clinical Oncology (2010)

7073 Background: The multidisciplinary lung cancer group was established at the Memphis VA Hospital in 2000, and during the first 6 years we followed 1433 patients with suspicious pulmonary lesions. We report the follow up of 381 of these patients presenting with SPNs. Methods: All patients had a nodule or nodules < 3 cm in diameter. After initial evaluation including CT scanning, patients received either an attempt at direct histologic diagnosis with bronchoscopy, fine needle biopsy or surgery, or were otherwise followed in our clinic for a minimum of 2 years. Results: Of the 381 patients, 335 were evaluable for complete analysis. Patient characteristics included: 70% Caucasian, 29% Afro American, 96% male, 90% smokers, and a mean age of 65 years. Physical appearance of the nodule at initial examination was predictive of neoplasm if: calcified (28 pts) in 7%, nodular (202 pts) in 20%, lobular (26 pts) in 54%, spiculated (62 pts) in 70% and growth during follow-up (40 pts) in 93%. Size at initial evaluation was predictive of neoplasm if: < 1 cm (90 pts) in 7%, 1-<2cm (164 pts) in 30%, 2-<3cm (70 pts) in 66%. Seventy-two patients (21% of SPNs) had a surgical resection by wedge resection, lobectomy or pneumoectomy. Sixty patients were found to have a carcinoma (82%); 52 (73%) to have NSCLC and 11 (15%) patients had granulomas. Thirty patients with NSCLC were stage IA with a mean age of 72 years and a median survival of 54 months. Twelve patients had stage IB, 5 patients had stage IIA, 1 had stage IIB and 4 had stage IIIB. Conclusions: Evaluation of patients with SPNs by a multidisciplinary team is a relatively efficient method of finding early primary lung cancers. No significant financial relationships to disclose.
Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma (MM): Distinguishing early failures (EF) from sustained control (SC).
Authors: B. Barlogie, J. D. Shaughnessy, J. Haessler, A. Hoering, F. Van Rhee, E. J. Anaissie, J. Crowley
Journal: Journal of Clinical Oncology (2010)

8019 Background: With the introduction of GEP analysis in Total Therapy 2 (TT2) and validation in Total Therapy 3 (TT3), GEP-defined high-risk, present in ∼15% of patients, has emerged as the dominant adverse feature for both overall survival (OS) and event-free survival (EFS) and, despite achieving a similar rate of complete response (CR) as in low-risk MM, also for CR duration (CRD). Thus, median OS and EFS remain dismal not exceeding 3 and 2 years, respectively. Recognizing, however, that 10% to 20% of high-risk patients enjoy extended survival, we examined the presenting features and response characteristics that may distinguish this favorable subset. Methods: Our MM data base was scrutinized for TT2 and TT3 patients who had high-risk baseline GEP features. Modeling survival curves by an exponential function, 2 subsets could be defined comprising one with steep decline in OS and a second with a shallow slope/plateau. Baseline variables of these 2 groups were determined and logistic regression applied to distinguish their characteristics. Results: We identified, among the combined TT2 and TT3 populations, 123 subjects with GEP-defined high-risk features who, by modeling, could be segregated into 2 groups with early failure (EF, n=65) and sustained control (SC, n=58). According to logistic regression, the SC-distinguishing features included GEP risk score (OR=0.25; p=0.006) and delTP53 (OR=0.20; p=0.015), of which only delTP53 survived the multivariate model (OR=0.26; p=0.008). None of the other GEP-derived variables (molecular subgroup, amp1q21, del1p) or other standard variables (CA, B2M, CRP, albumin) were discriminatory, with a borderline effect of LDH ≥190U/L (OR=0.51; p=0.062). Conclusions: Among GEP-defined high- risk MM, ∼50% could be distinguished as having SC which, in contrast to EF, was characterized by lower risk score and delTP53 frequency. Data will be presented on SC versus EF discriminating genes. No significant financial relationships to disclose.
A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer.
Authors: M. Aglietta, C. Barone, M. Muliello, C. Bagalà, D. Ferraro, K. D. Fly, B. Huang, F. Leone
Journal: Journal of Clinical Oncology (2010)

4134 Background: CP-675,206 (tremelimumab) is a fully human monoclonal antibody which binds to the CTLA4 molecule on the surface of activated T lymphocytes and T regulatory cells. It is thought to stimulate the immune system to attack tumor cells by blocking the negative regulatory signal of CTLA4. Primary objective of the study is to determine the maximum tolerated dose (MTD) and evaluate the safety profile of CP-675,206 in combination with gemcitabine for the treatment of patients with previously untreated metastatic pancreatic cancer. Methods: All patients received a 1-month gemcitabine-only lead-in period. Gemcitabine (1,000 mg/m2) was administered for 3 weekly doses followed by one week of rest. For patients who successfully completed the lead-in period, escalating doses of CP-675,206 were added to gemcitabine. Three dose levels of CP-675,206 were tested (6 mg/kg, 10 mg/kg, and 15 mg/kg). CP-675,206 was administered intravenously on day 1 of each 12-week cycle. Dose limiting toxicities (DLTs) related to CP-675,206 therapy were evaluated during the first 6 weeks after the first dose of CP-675,206. Results: A total of 18 pts (M/F = 12/6; median age approximately 53; range 29-73) were enrolled in the study. The median number of CP-675,206 cycles was 2 (range 1-3). No DLTs related to CP-675,206 were observed at any dose level. Most frequent grade 3-4 toxicities were anemia (4/18), transaminases increase (3/18), bilirubin increase (3/18). All G3-4 AEs were considered related to gemcitabine or disease progression. Two out of 17 evaluable pts obtained confirmed partial responses. Conclusions: CP-675,206 in combination with gemcitabine was well tolerated up to the dose level of 15 mg/kg. A next step of the study is ongoing. It will evaluate the safety profile of CP-675,206 when administered simultaneously to gemcitabine without a gemcitabine-only lead-in period. No significant financial relationships to disclose.
Molecular cytogenetic characterization of the chromosome 11 and 18 breakpoints in the t(11;18)(q21;q21) associated with malt lymphomas
Authors: J Dierlamm, Iwona Wlodarska, M Stefanova, JM Hernandez, Lucienne Michaux, Gregor Verhoef, M Gonzales, DK Hossfeld, Chris Peeters, Anne Hagemeijer-Hausman, Herman Van den Berghe, Peter Marynen
Journal: Blood (1998)
‘Keeping you active’—the Australasian College of Sport and Exercise Physicians
Authors: Hamish Osborne
Journal: British Journal of Sports Medicine (2016)

Welcome to the Australasian College of Sport and Exercise Physicians' (ACSEP) special edition of BJSM . This edition has a selection of articles that represent all the college stands for and is represented in our recent name change. The position statement on the use of mesenchymal stem cells in sport and exercise medicine ( see page 1237 ) has been recently updated by the college board and should be read in conjunction with our latest editorial in this issue ( see page 1229 ).

A recent delegation from the college recently visited our Singapore colleagues and they were very impressed by the progress they have made in integrating exercise medicine into public hospital medicine ( see page 1232 ). While New …
Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD:Â Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003
Authors: Jack Bartram, David O'Connor, Amir Enshaei, Anthony V Moorman, Christine Harrison, Rachel Wade, Rachel Clack, Jeremy Hancock, Sujith Samarasinghe, John Moppett, Ajay J. Vora, Nicholas Goulden
Journal: Blood (2015)
Cytogenetic results in 467 cases of B-cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria
Authors: JM Hernandez, Christina Mecucci, A Criel, P Meeus, Lucienne Michaux, A Louwagie, A Van Hoof, Marc Boogaerts, Gregor Verhoef, Herman Van den Berghe
Journal: Blood (1994)
Temperature responsive porous silicon nanoparticles for cancer therapy – spatiotemporal triggering through infrared and radiofrequency electromagnetic heating
Authors: Konstantin Tamarov, Wujun Xu, Liubov Osminkina, Sergey Zinovyev, Pasi Soininen, Andrey Kudryavtsev, Maxim Gongalsky, Azha Gaydarova, Ale Närvänen, Victor Timoshenko, Vesa-Pekka Lehto
Journal: Journal of Controlled Release (2016)
South-east Asian Zika virus strain linked to cluster of cases in Singapore, August 2016
Authors: Sebastian Maurer-Stroh, Tze-Minn Mak, Yi-Kai Ng, Shiau-Pheng Phuah, Roland G Huber, Jan K Marzinek, Daniel A Holdbrook, Raphael TC Lee, Lin Cui, Raymond TP Lin
Journal: Eurosurveillance (2016)

Zika virus (ZIKV) is an ongoing global public health emergency with 70 countries and territories reporting evidence of ZIKV transmission since 2015. On 27 August 2016, Singapore reported its first case of local ZIKV transmission and identified an ongoing cluster. Here, we report the genome sequences of ZIKV strains from two cases and find through phylogenetic analysis that these strains form an earlier branch distinct from the recent large outbreak in the Americas.
An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE® Antibody Construct Blinatumomab
Authors: Nicola Goekbuget, Hagop Kantarjian, Monika Brüggemann, Anthony Stein, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Leonard Heffner, Françoise Rigal-Huguet, Mark Litzow, Susan O'Brien, Gerhard Zugmaier, Catherine Jia, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Stephen J. Forman, Max S. Topp
Journal: Blood (2014)
Radiofrequency ablation of lung metastases arising from sarcoma.
Authors: J. Palussiere, A. Italiano, A. Avril, E. Descat, N. Bin Bui
Journal: Journal of Clinical Oncology (2010)

10041 Background: To evaluate radiofrequency ablation (RFA) in the treatment of lung metastases arising from sarcoma. Methods: Between 2002 and 2009, out of 100 patients treated for metastatic sarcoma, 47 presented lung metastases and no extra-pulmonary metastases were noted for 36. Twenty-nine patients (mean age 51 yrs) with a maximum of 5 lung metastases curable by RFA were followed prospectively. Lung RFA was performed under general anesthesia with CT guidance. The different endpoints were: complications, local efficacy (assessed by CT images during the follow-up period), survival (overall survival: OS; recurrence free survival : RFS). Results: Forty-seven metastases were treated by RFA. Mean size of metastases was 9mm (range 4-40mm). Median time between primary tumor and lung metastases was 26 months. Mean time between appearance of lung metastases and RFA was 5.5 months. For 2 patients, surgery was performed on one side and RFA on the other. For 27 patients, RFA treatment was carried out for all metastases. Median follow-up time was 50 months (28-72 months). Pneumothorax was the most frequent complication and occurred in 68.7% of the procedures. The 1 and 3-year OS rates were 92.2% and 65.2%, RFS was 7 months (3.5-10 months). Five recurrences on a RFA site were noted during follow-up, 4 were treated with chemotherapy due to evolution of the metastatic disease, one with surgery. Conclusions: RFA is safe and efficient in the treatment of lung metastases arising from sarcoma. In this series, the 3-year OS compares with the results obtained by surgical lung resection. As local treatment is thought to contribute to the survival of sarcoma patients with lung metastases, RFA may be a low morbidity alternative to surgery. No significant financial relationships to disclose.
Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.
Authors: Omer Koc, Charles Redfern, Peter Wiernik, Fred Rosenfelt, Jane Winter, Troy Guthrie, Lawrence Kaplan, Peter Holman, John Densmore, John Hainsworth, Thomas S. Lin, Rene Castillo, Nalini Janakiraman, John Bender
Journal: Blood (2007)
A Therapeutic Platelet Transfusion Strategy without Routine Prophylactic Transfusion Is Feasible and Safe and Reduces Platelet Transfusion Numbers Significantly: Preliminary Analysis of a Randomized Study in Patients after High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation
Authors: Hannes Wandt, Knut Wendelin, Kerstin Schaefer-Eckart, Markus Thalheimer, Mario Stephan Schubert, Roland Conradi, Rainer Schwerdtfeger, Lothar Leimer, Martin Kaufmann, Gottfried Dölken, Anne Friederike Klenner, Markus Schaich, Gerhard Ehninger
Journal: Blood (2008)
Outcome of patients with PDGFRA D842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease. A study performed with the EORTC Soft Tissue and Bone Sarcoma Group
Authors: P Biron, PA Cassier, E Fumagalli, A Blesius, Maria Debiec-Rychter, A Adenis, J Verweij, P Hohenberger, J-Y Blay, P Casali
Journal: Journal of Clinical Oncology (2010)
Phase 2, Randomized Trial (CONCERT-2) of Panitumumab (PMAB) Plus Radiotherapy (PRT) Compared with Chemoradiotherapy (CRT) in Patients (PTS) with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)
Authors: J. Giralt, J.M. Trigo, S. Nuyts, E.M. Ozsahin, K. Skladowski, G. Hatoum, J. Daisne, A. Zhang, K. Oliner, A. Vanderwalde
Journal: Annals of Oncology (2012)
The Role of <i>PIEZO2</i> in Human Mechanosensation
Authors: Alexander T. Chesler, Marcin Szczot, Diana Bharucha-Goebel, Marta Čeko, Sandra Donkervoort, Claire Laubacher, Leslie H. Hayes, Katharine Alter, Cristiane Zampieri, Christopher Stanley, A. Micheil Innes, Jean K. Mah, Carla M. Grosmann, Nathaniel Bradley, David Nguyen, A. Reghan Foley, Claire E. Le Pichon, Carsten G. Bönnemann
Journal: New England Journal of Medicine (2016)

The senses of touch and proprioception evoke a range of perceptions and rely on the ability to detect and transduce mechanical force. The molecular and neural mechanisms underlying these sensory functions remain poorly defined. The stretch-gated ion channel PIEZO2 has been shown to be essential for aspects of mechanosensation in model organisms.We performed whole-exome sequencing analysis in two patients who had unique neuromuscular and skeletal symptoms, including progressive scoliosis, that did not conform to standard diagnostic classification. In vitro and messenger RNA assays, functional brain imaging, and psychophysical and kinematic tests were used to establish the effect of the genetic variants on protein function and somatosensation.Each patient carried compound-inactivating variants in PIEZO2, and each had a selective loss of discriminative touch perception but nevertheless responded to specific types of gentle mechanical stimulation on hairy skin. The patients had profoundly decreased proprioception leading to ataxia and dysmetria that were markedly worse in the absence of visual cues. However, they had the ability to perform a range of tasks, such as walking, talking, and writing, that are considered to rely heavily on proprioception.Our results show that PIEZO2 is a determinant of mechanosensation in humans. (Funded by the National Institutes of Health Intramural Research Program.).
eHuman subcutaneous and visceral fat inflammatory gene signatures accurately predict histological severity of non-alcoholic fatty liver disease
Authors: Johannie Du Plessis, Jos van Pelt, Hannelie Korf, Chantal Mathieu, Matthias Lannoo, Gary K Fetter, Simon Nayler, Tessa van der Merwe, Luc Van Gaal, Sven M Francque, Frederik Nevens, Schalk Van der Merwe
Journal: Hepatology (2014)
Towards patient-specific modeling of mitral valve repair: 3D transesophageal echocardiography-derived parameter estimation
Authors: Fan Zhang, Jingjing Kanik, Tommaso Mansi, Ingmar Voigt, Puneet Sharma, Razvan Ioan Ionasec, Lakshman Subrahmanyan, Ben A. Lin, Lissa Sugeng, David Yuh, Dorin Comaniciu, James Duncan
Journal: Medical Image Analysis (2016)
Myelodysplastic Syndrome-Derived Stromal Cells Support Leukemia-Initiating Cells and Contradirectly Eliminate Normal CD34+ Clonogenic Cells
Authors: Hiroto Horiguchi, Masayoshi Kobune, Shohei Kikuchi, Satoshi Iyama, Kohichi Takada, Kazuyuki Murase, Kaoru Ono, Yusuke Kamihara, Akari Hashimoto, Ayumi Tatekoshi, Tsuyoshi Hayashi, Tsutomu Sato, Koji Miyanishi, Yasushi Sato, Rishu Takimoto, Junji Kato
Journal: Blood (2013)
High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma –Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group
Authors: Gerald Illerhaus, Kristina Fritsch, Ingo Schmidt-Wolf, Roland Schroers, Gerlinde Egerer, Agnieszka Korfel, Tobias Birnbaum, Monika Lamprecht, Nikolas von Bubnoff, Hans-Heinrich Wolf, Stephan Stilgenbauer, Martin Trepel, Robert Möhle, Claudia Hader, Gabriele Ihorst, Heidi Fricker, Benjamin Kasenda, Elisabeth Schorb, Jürgen Finke
Journal: Blood (2014)
Discovery and development of CP-724714, a selective HER2 receptor tyrosine kinase inhibitor
Authors: J. Jani, E. Barbacci, S. Bhattacharya, C. Boos, M. Campbell, T. Clark, K. Coleman, R. Connell, T. Cosker
Journal: Journal of Clinical Oncology (2004)

3122 Background: The HER2 (neu/erbB2) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary and stomach. Amplification of the HER2 gene and over-expression of this membrane receptor tyrosine kinase has been implicated in tumor growth, sensitivity to standard chemotherapy, prognosis of patients and disease free survival. Methods: Novel compounds were evaluated as inhibitors of recombinant HER2 tyrosine kinase-catalyzed phosphorylation of poly-glu/tyr and of the EGF-induced autophosphorylation of cellular epidermal growth factor receptor or a chimeric protein consisting of the EGFR extracellular domain/HER2 intracellular domain. The title inhibitor was further evaluated for its ability to reduce HER2 phosphorylation and growth in human tumor xenografts of athymic mice. Results: CP-724,714, a potent, orally active HER2 inhibitor, was identified and characterized for further development. This compound inhibits HER2 kinase (IC50 3.8 ng/ml) and is selective for HER2 vs. HER1, HER4 and other tyrosine kinases examined. CP-724714 reduces EGF-induced HER2 receptor phosphorylation in NIH 3T3 cells expressing a chimeric receptor consisting of the EGFR extracellular domain and the HER2 intracellular domain (IC50 15 ng/ml) and the growth of SKBr3 cells (IC50 25 ng/ml). Pre-clinical findings suggest that CP-724,714 is an orally bio-available compound with moderate clearance (11–12 ml/min/kg), and a low probability of drug:drug interactions. It reduces HER2 autophosphorylation of tumors in vivo (ED50 ∼ 19 mg/kg, EC50 ∼ 980 ng/ml), after oral administration to athymic mice bearing FRE erbB2 tumors (Fisher rat embryonic fibroblasts over-expressing HER2), and inhibited the growth of these tumors as well as human tumor xenografts. In nonclinical toxicology studies up to 1-month in duration, CP-724,714 was relatively well-tolerated in both Sprague-Dawley rats and Beagle dogs. Conclusions: CP-724714 is a novel HER2 inhibitor now in Phase I clinical trials. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Pfizer
Comparison of plasma ctDNA from the portal and peripheral veins of resectable CRC patients.
Authors: Xin-Xing Li, Jin-Zhong Chen, Grace Q. Zhao, Yanping Sun, Yi Wang, Canping Ruan, Shifeng Teng, Zexing Shan, Jia Zang, Hou-Shan Yao, Shengrong Lin, Kang Ying, Zhi-Qian Hu
Journal: Journal of Clinical Oncology (2016)

e23028 Background: Circulating tumor DNA (ctDNA) holds great potential as a biomarker for cancer management. Unfortunately, with a half-life of < 2hrs, ctDNA is present in miniscule quantities and can go undetected in peripheral blood. We hypothesized that blood collected from the portal vein may yield higher quantities of ctDNA than that collected elsewhere for colorectal cancers (CRC) due to the passage of blood from gastrointestinal organs through the portal vein prior to circulation. Methods: 10mL of peripheral blood was collected from 12 CRC patients prior to or during tumor removal surgery during which an additional 10 mL of blood drawn from the portal vein. ctDNA fragment length and concentration was measured for every pair of the resulting ctDNA, along with tissue gDNA, was sequenced using Accu-Act, a NGS panel of 61 genes which have implication of cancer treatments. Concordance of ctDNA mutation profiles from both collection sites and tumor were compared. Results: ctDNA was detected in all 12 sample pairs and a comparison of ctDNA from both collection sites revealed similar fragment lengths and concentration (12.26ng/ml, and peripheral vein: 10.83ng/ml). Little difference in concordance (compared to tumor) was observe. Though the average minor allele frequency of somatic mutations from portal venous ctDNA was slightly higher than that of peripheral venous ctDNA, the difference is not substantial. A mumber of mutaions with low allele frequcy (down to 0.1%, 2 copies), were detected in both sites, and from two independent DNA extractions from each sites. Conclusions: We have demonstrated the feasibility of obtaining portal venous ctDNA and reported no substantial difference between portal venous and peripheral venous ctDNA. Even the sensitivity and reporducbility of our Nebula-Firefly are very high, this analysis is still susceptible to sampling errors associated with the low copy number of mutated ctDNA in circulation and larger studies may provide more conclusive results.
Dynamic contrast-enhanced ct in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method to monitor treatment?
Authors: J. S. W Lind, M. R Meijerink, A. C Dingemans, C van Kuijk, M Ollers, Dirk De Ruysscher, P. E Postmus, E. F Smit
Journal: Journal of Thoracic Oncology (2010)